OUR MISSION

 

With leading efforts in neuropathic and osteoarthritic pain, we seek to transform the treatment of chronic inflammatory disease with a new gene therapy that uses a non-viral approach designed to alleviate the high burden on patient lives from a broad number of diseases and address unmet need for millions.

​

​

OUR APPROACH FOCUSES ON NATURALLY RESTORING THE BODY TO CYTOKINE HOMEOSTASIS

​

A healthy, strong body lives in a state of equilibrium.  Every day, it detects potential signals of injury or chronic disease progression and naturally restores itself by finely balancing anti-inflammatory cytokines and pro-inflammatory mediators.  Unfortunately, when the body’s immune system is unbalanced, inflammation can flare and persist over long periods of time.  This results in a myriad of diseases and associated symptoms, including chronic, debilitating pain that prevents millions of people from living healthy productive lives.

 

Xalud Therapeutics aims to break this cycle by developing a new therapeutic approach that leverages the body’s intrinsic immune signaling, stimulates the resolution pathway and resolves the pathologic inflammation at the root of chronic inflammatory conditions. By locally delivering the upstream regulator of multiple inflammatory pathways to the site of inflammation, our plasmid DNA gene therapy has the potential to normalize the immune system, reduce tissue damage and diminish associated sequelae – including debilitating pain. Our clinical programs will explore a broad array of inflammatory diseases and have the potential to provide effective long-lasting relief, a favorable safety profile and possible disease modification. Unlike viral gene therapies, our non-viral delivery technology is not limited to single-dose use.

 

We are harnessing the power of interleukin-10 (IL-10), a potent cytokine that acts as a master regulator for multiple inflammatory pathways. Our lead product candidate, XT-150 is a locally-injectable plasmid DNA gene therapy expressing IL-10v, a proprietary modified variant of human interleukin-10 (IL-10). XT-150 is currently being evaluated in additional clinical trials for the treatment of osteoarthritis of the knee and neuropathic pain.